Gu Gang of HNA Group: 4 bankruptcy meeting processes of RMB 2 trillion declaration of creditor's rights have been successfully completed, waiting for the ruling

Beyond Capital: Why Europe Needs Industrial Partners, Not Just Investors

Europe’s reindustrialization is creating new opportunities for Chinese companies. However, the winners will not necessarily be those seeking quick acquisitions or rapid market access. The real opportunities belong to companies capable of embedding themselves into Europe’s industrial ecosystem and supporting the long-term transformation of local industries.

Kanghong’s Conbercept Receives Marketing Authorization in Guyana

Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).

ByteDance’s Proposed US$20 Billion Offshore Loan Draws More Than US$30 Billion of Demand

ByteDance (字节跳动) has drawn more than US$30 billion of demand for a proposed syndicated loan that could become its largest offshore borrowing, Bloomberg reported on Aug. 19, underscoring lenders’ appetite to finance the TikTok owner’s expanding artificial-intelligence infrastructure plans.

Unpacking China | Key Chinese Firms to Watch This Week （02/08/2026-08/08/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Wantai BioPharm’s Nine-Valent HPV Vaccine Wins First Overseas Approval in Thailand

Wantai BioPharm (万泰生物) announced on Aug. 11 that the nine-valent HPV vaccine developed by its wholly owned subsidiary, Xiamen Innovax Biotech (万泰沧海), has received marketing authorization from Thailand’s Food and Drug Administration. The approval marks the vaccine’s first clearance outside China and an important step in Wantai BioPharm’s international expansion.